Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This short hairpin RNA (shRNA) is an RNA interference (RNAi) therapeutic candidate designed to target and silence the *SLC9A1* gene, which encodes the sodium-hydrogen exchanger 1 (NHE1) protein. NHE1 is a transmembrane transporter that maintains intracellular pH (pHi) by exchanging internal protons for external sodium ions. In various cancers, including kinase-mutated acute myeloid leukemia (AML), NHE1 is overexpressed or hyper-activated, leading to an alkaline intracellular environment that promotes cell survival, proliferation, and resistance to therapy. By knocking down NHE1 expression, this shRNA induces intracellular acidification and triggers apoptosis. Developed by researchers at the University of Hong Kong, this modality has demonstrated the ability to suppress leukemic growth in vivo and synergize with tyrosine kinase inhibitors and chemotherapy by altering the transmembrane pH gradient.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on short hairpin RNA targeting sodium-hydrogen exchanger 1.